Related Experiment Video

Updated: Jun 10, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination

Roberto Chiarle1, Cinzia Martinengo, Cristina Mastini

  • 1Center for Experimental Research and Medical Studies, University of Torino, Via Santena 7, 10126 Torino, Italy. roberto.chiarle@unito.it

Nature Medicine
|May 13, 2008
PubMed

Insights

DNA vaccination targeting anaplastic lymphoma kinase (ALK) shows potent, long-lasting protection against lymphoma in mice. Combining chemotherapy with ALK vaccination significantly improved survival, highlighting ALK as a promising tumor antigen for cancer vaccines.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Effective cancer vaccines require tumor-specific antigens essential for tumor maintenance.
  • Idiotype vaccination has shown promise for lymphoma treatment.
  • Anaplastic large cell lymphoma (ALCL) often involves translocated anaplastic lymphoma kinase (ALK) fusion proteins crucial for tumor growth.

Purpose of the Study:

  • To investigate the potential of DNA vaccination targeting anaplastic lymphoma kinase (ALK) as a therapeutic strategy for ALCL.
  • To evaluate the efficacy and durability of ALK-targeted vaccination in a mouse model of lymphoma.

Main Methods:

  • DNA vaccination using plasmids encoding portions of the cytoplasmic domain of ALK.
  • Challenging vaccinated mice with ALK-positive (ALK+) lymphomas.
  • Assessing tumor growth, survival rates, and immune responses (interferon-gamma, CD8+ T cell cytotoxicity).

Main Results:

  • DNA vaccination with ALK elicited potent and long-lasting protection against both local and systemic lymphoma growth in mice.
  • Vaccination induced ALK-specific interferon-gamma responses and CD8+ T cell-mediated cytotoxicity.
  • A combination of chemotherapy and ALK vaccination significantly enhanced the survival of mice with ALK+ lymphomas.

Conclusions:

  • Anaplastic lymphoma kinase (ALK) is a suitable tumor antigen for vaccination-based therapies against ALCL.
  • ALK-targeted DNA vaccination demonstrates significant therapeutic potential for ALCL and other ALK+ tumors.
  • Combination therapy of chemotherapy and ALK vaccination offers a promising strategy to improve outcomes in ALK+ lymphomas.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis07:45

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

Published on: January 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...